Market Research Report
Smoking Cessation-Market Insights, Epidemiology, and Market Forecast-2030
|Smoking Cessation-Market Insights, Epidemiology, and Market Forecast-2030|
DelveInsight Business Research LLP
Content info: 190 Pages
Delivery time: 2-10 business days
DelveInsight's 'Smoking Cessation-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the Smoking Cessation, historical and forecasted epidemiology as well as the Smoking Cessation market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Smoking Cessation market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Smoking Cessation market size from 2017 to 2030. The Report also covers current Smoking Cessation treatment practice/algorithm, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities, and assesses the underlying potential of the market.
Study Period: 2017-2030
Smoking cessation is the process of discontinuing tobacco smoking. When a person smokes tobacco in cigarettes, cigars or pipes, they absorb toxins that can lead to various health problems such as diabetes, cancer, chronic obstructive pulmonary disease (COPD), heart diseases, lung diseases, etc.
The main barrier to smoking cessation is nicotine addiction. Some of the most common nicotine withdrawal symptoms smokers face when they try to quit smoking include craving for smoking, mood swings, insomnia, constipation, increased appetite, anxiety, etc.
Stopping smoking brings about a variety of symptoms associated with physical and psychological withdrawal. Most symptoms decrease sharply during the first few days of quitting, followed by a continued, but slower rate of decline in the second and third week of abstinence. For some people, coping with withdrawal symptoms is like "riding a roller coaster"-there may be sharp turns, slow climbs, and unexpected plunges. Most symptoms pass within 2-4 weeks after stopping.
The treatment of smoking includes various options such as nicotine replacement therapy (NRT), non-nicotinic pharmacological therapies, behavioral therapies, and counseling.
Varenicline (Champix) and bupropion-SR (Zyban) are approved for smoking cessation. Nortriptyline and clonidine are also used in smoking cessation as off-label medicines.
In the United States, NRT is available over the counter or by prescription as patches, gum, and lozenges, and by prescription only as a nasal spray and oral inhaler. NRT provides nicotine to reduce withdrawal symptoms, including irritability, anxiety, difficulty concentrating, dysphoria, hunger, weight gain, and sleep disturbances, which occur when a smoker stops smoking.
Non-pharmacological treatments for tobacco dependence include behavioral skills training using cognitive behavioral therapy techniques, motivational interviewing, and incentives to motivate and reinforce behavior change.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Smokers, Gender-specific Diagnosed Prevalent Cases of Smokers, Age-specific Diagnosed Prevalent Cases of Smokers and Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The epidemiology segment also provides the Smoking Cessation epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the Smoking Cessation report encloses the detailed analysis of Smoking Cessation current therapies, mid-phase, and late-stage pipeline drugs. It also helps to understand the Smoking Cessation clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug, and the latest news and press releases.
Smoking Cessation Marketed Drugs
Varenicline is a medication used for smoking cessation aids. It works by blocking the pleasant effects of nicotine (from smoking) on the brain. It is used together with behavior modification and counseling support to help stop smoking. In May 2006, the US FDA approved varenicline (Chantix, Champix) for use in smoking cessation; it was the first oral non-nicotine treatment licensed by the FDA. It was also approved in the EU and Japan for smoking cessation. Patients should be treated with Chantix for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks of treatment with Chantix is recommended to increase the likelihood of long-term abstinence further.
Varenicline binds with high affinity and selectivity at α4B2 neuronal nicotinic acetylcholine receptors. The efficacy of Chantix in smoking cessation is believed to be the result of varenicline's activity at the α4B2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these receptors.
Bupropion is a selective inhibitor of the neuronal reuptake of catecholamines (noradrenaline and dopamine) with minimal effect on the re-uptake of indolamines (serotonin). It is indicated as an aid to smoking cessation treatment. The exact mechanism by which Zyban enhances the ability of patients to abstain from smoking is not known but is presumed to be related to noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit the reuptake of serotonin. Bupropion does not inhibit monoamine oxidase. The FDA approved it in 1997. It is also approved in the EU for the treatment of smoking cessation.
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity, in clinical development for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and smoking cessation. The drug consists of dextromethorphan (DM) and bupropion and utilizes Axsome's metabolic inhibition technology. The DM component of AXS-05 is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, sigma-1 receptor agonist, and an inhibitor of the serotonin and norepinephrine transporters. The bupropion component of AXS-05 serves to increase the bioavailability of DM and is a norepinephrine and dopamine reuptake inhibitor. Both components are nicotinic acetylcholine receptor antagonists and have demonstrated anti-inflammatory properties. The company plans to meet with the FDA in the second half of 2020 to discuss the continued clinical development of AXS-05 as an aid to smoking cessation treatment.
Nadolol (INV102): Chronic Airway Therapeutics
Nadolol (INV102) is a beta-adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium to treat chronic respiratory diseases. Used acutely, Nadolol blocks both B1 and B2 receptors, causing a decrease in heart rate and blood pressure via B1 receptors, which are located predominantly in the heart, and causing airway constriction via B2 receptors, located predominantly in the bronchial muscle of the airways. The drug is currently marketed under various brands including Corgard and Novo-Nadolol. The company evaluated nadolol in a phase II clinical trial, and results show that it is safe and effective in smoking cessation.
Cytisinicline (cytisine): Achieve Life Sciences
Cytisinicline (also known as cytisine) is an oral, plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe (as Tabex) for more than 20 years. Cytisinicline's dual-acting MOA specifically targets the α4B2 nicotine receptor. Through its partial agonist/partial antagonist activity, it is believed to help reduce nicotine cravings, withdrawal symptoms, and reward and satisfaction associated with smoking. The company is launching a phase III clinical trial in Q4 with designs and NDA plans already reviewed with the FDA. It was also studied in phase III clinical trial comparing cytosine and varenicline. Achieve Life Sciences also completed the development of phase II ORCA-V1 trial protocol to evaluate cytisinicline in this rapidly growing population of e-cigarette users. Currently, the company is pursuing non-dilutive funding sources to help support this initiative.
There are effective treatments that support tobacco cessation, including both behavioral therapies and FDA-approved medications. There are 89 distinct products and services available today for smoking cessation, alongside 12 smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapy (NRT) in the form of a transdermal patch, gum, nasal spray, oral inhaler, and lozenges; bupropion; and, most recently, varenicline. Nortriptyline and clonidine have been shown in clinical trials to promote smoking cessation, but regulatory authorities have not approved them for this purpose.
In the EU, varenicline (Champix) and bupropion-SR (Zyban) are approved for smoking cessation. Cytisine is a generic agent currently manufactured by Sopharma as Tabex and by Aflofarm Pharma as Desmoxan. It has been available both with and without prescription for smoking cessation since the 1960s, largely in Eastern Europe. The basic patent of Chantix/Champix is about to expire in 2021 in the EU and in 2022 in Japan. In Japan, varenicline (Champix), NRT, and some off-label therapies are used for smoking cessation. Bupropion-SR is not licensed in Japan for smoking cessation.
For smokeless tobacco users, counseling and support in changing behavior appear to be effective, while the evidence for nicotine replacement and other drugs is weak. Nonpharmacologic therapy, such as individual or group counseling, is necessary to address the important role of conditioning in tobacco addiction, which is not completely addressed using pharmacologic means. Briefly, ideal characteristics of effective nonpharmacologic treatment include those that improve skills necessary to achieve and maintain abstinence, such as those that teach coping mechanisms for craving and aversive abstinence symptoms.
According to DelveInsight, Smoking Cessation 7MM is expected to change in the study period 2017-2030.
This section provides the total Smoking Cessation market size and; market size by therapies in the United States.
The total Smoking Cessation market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Smoking Cessation market size and market size by therapies in Japan are provided.
This section focuses on the rate of uptake of the drugs expected to get launched in the market during the study period 2017-2030. The analysis covers Smoking Cessation market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Smoking Cessation emerging therapies.
Reimbursement Scenario in Smoking Cessation
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
We perform competitive and market Intelligence analysis of the Smoking Cessation market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.